EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
/PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq:...
The pharmaceutical stock dropped after announcing so-so clinical trial results.
Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...
The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...
Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive...
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...
Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...